首页 | 本学科首页   官方微博 | 高级检索  
检索        

雷帕霉素和顺铂对Hep-2细胞DNA切除修复交叉互补基因1表达的协同作用
引用本文:雷文斌,贾涛,苏振忠,文卫平,祝小林.雷帕霉素和顺铂对Hep-2细胞DNA切除修复交叉互补基因1表达的协同作用[J].中山大学学报(医学科学版),2011,32(3).
作者姓名:雷文斌  贾涛  苏振忠  文卫平  祝小林
作者单位:中山大学附属第一医院耳鼻咽喉科医院//耳鼻咽喉科学研究所,广东广州,510080
基金项目:国家自然科学基金(81072224);中山大学青年培育项目(10ykpy10);广东省科技计划项目
摘    要: 【目的】 探讨mTOR抑制剂雷帕霉素和顺铂对喉癌Hep-2细胞协同作用的机制。【方法】 Hep-2细胞在雷帕霉素单药浓度为5、20 μmol/L;顺铂单药浓度为3、12 μmol/L;联合用药浓度为雷帕霉素5 μmol/L联合顺铂3 μmol/L中分别培养,检测Hep-2细胞AKT, mTOR, S6K和ERCC1(DNA切除修复交叉互补基因1)蛋白分别在3,6,12,24,48 h的表达情况。【结果】 雷帕霉素单药干预Hep-2细胞12 h后,p-mTOR、S6K及ERCC-1表达表达下调,与对照组比较显著性,AKT蛋白表达在48 h增加,与对照组比较差异有统计学意义;顺铂单药干预Hep-2细胞时,ERCC-1表达12 h后增加,与对照组比较差异有统计学意义,p-mTOR、AKT和S6K蛋白表达差异无统计学意义;联合用药时,AKT蛋白表达在48 h增加,与对照组比较差异有统计学意义,p-mTOR、S6K、在12 h后表达下降,与对照组比较差异有统计学意义,ERCC-1的表达与对照组比较没有差异有统计学意义。【结论】 雷帕霉素和顺铂联合应用时,呈协同作用,这可能与雷帕霉素能诱导肿瘤细胞凋亡及影响ERCC-1的表达有关。

关 键 词:雷帕霉素  Akt/mTOR  顺铂  Hep-2细胞  细胞凋亡  ERCC-1
收稿时间:2010-11-10;

Relationship between ERCC-1 Expression and Combined Effect of mTOR Inhibitor Rapamycin and Cisplatin on Survival of Hep-2 Cells In Vitro
LEI Wen-bin,JIA Tao,SU Zhen-zhong,WEN Wei-ping,ZHU Xiao-lin.Relationship between ERCC-1 Expression and Combined Effect of mTOR Inhibitor Rapamycin and Cisplatin on Survival of Hep-2 Cells In Vitro[J].Journal of Sun Yatsen University(Medical Sciences),2011,32(3).
Authors:LEI Wen-bin  JIA Tao  SU Zhen-zhong  WEN Wei-ping  ZHU Xiao-lin
Institution:LEI Wen-bin,JIA Tao,SU Zhen-zhong,WEN Wei-ping,ZHU Xiao-lin(Otorhinolaryngology Hospital//Otorhinolaryngology Institute,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China)
Abstract:【Objective】 To investigate the cytotoxic effect and mechanism of action of cisplatin and the mTOR inhibitor rapamycin on laryngeal cancer (Hep2) cells..【Methods】 Hep-2 cells were cultured in the presence of different concentrations of rapamycin, cisplatin or the two combined. A subset of cells was treated with rapamycin only at concentrations of 5 and 20 μmol/L. A further subset of cells was treated with cisplatin only at concentrations of 3 and 12 μmol/L. A final subset of cells was treated with media containing 5 μmol/L rapamycin and 3 μmol/L cisplatin combined. Western blot was used to determine expression of proteins p-Akt,p-mTOR, S6K, and ERCC-1 in 3, 6, 12, 24, and 48 h. 【Results】 mTOR, S6K and ERCC-1 protein levels significantly decreased after treating with rapamycin 12 h. AKT protein levels significantly increase after treating with rapamycin 48 h. ERCC-1 protein levels significantly increase after treating with cisplatin 12 h. No changes in AKT, p-mTOR and S6K protein expression were apparent for treating with cisplatin. S6K and p-mTOR protein levels significantly decreased after treating with combined drug 12 h. AKT protein levels significantly increase after 48 h. No changes in ERCC-1 protein expression were apparent for this treatment group.【Conclusions】 The synergistic effect of rapamycin and cisplatin improves their cytotoxicity on Hep2 cells. The expression of ERCC-1 influencing by rapamycin might be related to this.
Keywords:rapamycin  AKT/mTOR  cisplatin  Hep-2 cells  apoptosis  ERCC-1  
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中山大学学报(医学科学版)》浏览原始摘要信息
点击此处可从《中山大学学报(医学科学版)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号